You are here: Home » Companies » News
Business Standard

Pfizer sets up drug development centre at Chennai's IIT Research Park

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technology and Engineering (GT&E) Centre of Excellence.

Topics
Pfizer | Pfizer India | IIT-Madras

BS Reporter  |  BS Reporter 

Pfizer

has set up a global drug development centre at the IIT Madras Research Park in Chennai.

The company has invested $20 million in the 61,000 square feet research and technology centre at the IIT Madras Research Park. While this centre will be part of a network of 12 global centres set up worldwide, it is the first and only one at present being set up by in Asia.

The centre’s capabilities will include the development of both, active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) of differentiated products such as complex/value-added formulations, controlled-release dosage forms, device-combination products, lyophilised injections, powder-fill products, and ready-to-use formulations. The centre will develop and support products in global markets and Pfizer’s manufacturing centre worldwide.

“We are confident that it will allow for synergistic co-development of cutting-edge active pharmaceutical ingredients (API) and finished dosage form (FDF) processes under the same roof. The world-class scientific, technology and innovation-driven Research Park campus provides an ideal setting for our work,” said Sridhar, country manager, India.

The centre integrates two essential functions under the export-oriented undertaking of Pfizer Inc: Pharmaceutical Sciences (PharmSci) and global technology and engineering (GT&E) Centre of Excellence. PharmSci is dedicated to the development of anti-infectives, oncolytics, sterile injectables, anesthesia products, CNS products, and uniquely differentiated hospital products. GT&E pioneers next-generation API process and manufacturing technology to supply medicines to patients around the globe.

“It is encouraging to see a company like Pfizer make a significant investment in R&D in India, and on this prestigious IIT Madras Research Park campus. This centre will offer Indian scientists the opportunity to establish a global footprint in medical R&D. In the future, it will also allow for collaboration between industry and academia,” said J Radhakrishnan, principal secretary, Tamil Nadu Health and Family Welfare Department.

This 61,000 sq ft facility employs over 250 scientists and professionals from a range of scientific disciplines including formulation scientists and pharmacists, analytical scientists with expertise in process, analytical and formulation medicinal sciences, life Science specialists such as microbiologists and biotechnologists, chemical engineers, data scientists, and programme managers.

“Drug Development is one of the most important activities wherein technology meets medicine. Aligning the process with regulatory conditions using technology will not only quicken but enhance the quality of the process of drug development,” said V Kamakoti, director, IIT Madras.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, May 05 2022. 09:34 IST
RECOMMENDED FOR YOU
.